L'inhibition du TYK2 dans le psoriasis paradoxal. Un essai clinique pour évaluer l'effet du Deucravacitinib dans le psoriasis paradoxal en comparaison avec le traitement par placebo.

Drug: Deucravacitinib

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

1. Clinical diagnosis of Paradoxical Psoriasis caused by anti-TNF treatment, with with
Investigator Global Assessment = 2 and Body Surface Area = 2%

2. Females who are of child-bearing potential should be practicing highly-effective
contraception methods throughout the study and for 28 days after the last dose of
study drug;

3. Male subjects with a mechanical contraceptive method;

4. be in good health

5. be willing to have skin biopsies taken

Exclusion Criteria:

1. Use of any other anti-psoriatic therapy. Certain washout periods of treatments needs
to be respected

2. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days
prior to the Baseline visit or oral anti-infectives within 14 days prior to the
Baseline visit;

3. A positive serology test for hepatitis B, hepatitis C, HIV;

4. History of lymphoproliferative disease or of malignancy within the past 5 years.

5. Chronic recurring bacterial infections or active tuberculosis;

6. Positive pregnancy test at Screening and at the Baseline visit;

7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant
during the study;

8. History of clinically significant alcohol or drug abuse in the last 12 months

9. Known hypersensitivity to Deucravacitinib or any of its excipients

10. Current severe progressive or uncontrolled disease

11. Live vaccine within 12 weeks before Baseline Visit.